(NUVB) Nuvation Bio - Overview
Stock: Taletrectinib, Safusidenib, NUV-1511, NUV-868
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 80.0% |
| Relative Tail Risk | -14.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.31 |
| Alpha | 113.84 |
| Character TTM | |
|---|---|
| Beta | 1.275 |
| Beta Downside | 0.937 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.19% |
| CAGR/Max DD | 0.69 |
Description: NUVB Nuvation Bio January 25, 2026
Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharma focused on oncology therapeutics. Founded in 2018 and based in New York, the company’s pipeline centers on targeted small-molecule inhibitors and a drug-drug conjugate (DDC) platform.
Its lead candidate, **taletrectinib**, is an oral ROS1 inhibitor for ROS1-positive non-small cell lung cancer (NSCLC). In the most recent Phase 2 data (Q3 2025), taletrectinib achieved an objective response rate (ORR) of 55% with a median progression-free survival (PFS) of 8.2 months, meeting its primary efficacy endpoint and prompting a pre-BLA meeting with the FDA.
Additional pipeline assets include:
• **Safusidenib**, a mutant IDH1 inhibitor currently in a Phase 2 trial for IDH1-mutant cholangiocarcinoma, where interim analysis (Oct 2025) showed a disease control rate of 71%;
• **NUV-1511**, a DDC that links a cytotoxic payload to a tumor-targeting antibody, which reported a 30% tumor-size reduction in a basket trial of advanced solid tumors (Nov 2025);
• **NUV-868**, a selective BET-2 bromodomain inhibitor, now entering a Phase 1b dose-escalation study for triple-negative breast cancer (Jan 2026).
Financially, Nuvation reported cash and cash equivalents of **$115 million** at the end of 2025, sufficient for roughly **18 months** of runway at its current burn rate of $6–7 million per quarter. The company raised $45 million in a June 2025 private placement, pricing at a 30% discount to the prior month’s closing price, reflecting ongoing capital-raising pressure in the biotech sector.
Key sector drivers that shape Nuvation’s outlook include the projected **CAGR of ~7% for the global oncology drug market through 2030**, sustained investor appetite for precision-medicine assets, and the **U.S. FDA’s accelerated review pathways for targeted therapies**, which can shorten time-to-market for agents like taletrectinib.
For a deeper quantitative assessment of NUVB’s valuation dynamics, you may find it useful to explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -217.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -14.25 > 1.0 |
| NWC/Revenue: 1904 % < 20% (prev 18.8k%; Δ -16.9k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -190.0m > Net Income -217.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (342.4m) vs 12m ago 25.16% < -2% |
| Gross Margin: 54.26% > 18% (prev -0.11%; Δ 5436 % > 0.5%) |
| Asset Turnover: 4.56% > 50% (prev 0.47%; Δ 4.09% > 0%) |
| Interest Coverage Ratio: -203.2 > 6 (EBITDA TTM -215.0m / Interest Expense TTM 1.06m) |
Altman Z'' -1.53
| A: 0.85 (Total Current Assets 577.5m - Total Current Liabilities 68.1m) / Total Assets 601.6m |
| B: -1.79 (Retained Earnings -1.08b / Total Assets 601.6m) |
| C: -0.37 (EBIT TTM -216.4m / Avg Total Assets 586.6m) |
| D: 1.18 (Book Value of Equity 325.9m / Total Liabilities 275.7m) |
| Altman-Z'' Score: -1.53 = D |
Beneish M 1.00
| DSRI: 0.33 (Receivables 13.8m/4.25m, Revenue 26.7m/2.69m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 5.34 (AQ_t 0.03 / AQ_t-1 0.01) |
| SGI: 9.94 (Revenue 26.7m / 2.69m) |
| TATA: -0.05 (NI -217.5m - CFO -190.0m) / TA 601.6m) |
| Beneish M-Score: 5.36 (Cap -4..+1) = D |
What is the price of NUVB shares?
Over the past week, the price has changed by +8.78%, over one month by -32.86%, over three months by +13.55% and over the past year by +136.51%.
Is NUVB a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NUVB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.9 | 108.6% |
| Analysts Target Price | 11.9 | 108.6% |
| ValueRay Target Price | 5.5 | -3.9% |
NUVB Fundamental Data Overview February 01, 2026
P/B = 5.6178
Revenue TTM = 26.7m USD
EBIT TTM = -216.4m USD
EBITDA TTM = -215.0m USD
Long Term Debt = 47.1m USD (from longTermDebt, last quarter)
Short Term Debt = 7.49m USD (from shortTermDebt, last quarter)
Debt = 57.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.30b USD (1.80b + Debt 57.5m - CCE 549.0m)
Interest Coverage Ratio = -203.2 (Ebit TTM -216.4m / Interest Expense TTM 1.06m)
EV/FCF = -6.86x (Enterprise Value 1.30b / FCF TTM -190.2m)
FCF Yield = -14.58% (FCF TTM -190.2m / Enterprise Value 1.30b)
FCF Margin = -711.3% (FCF TTM -190.2m / Revenue TTM 26.7m)
Net Margin = -813.1% (Net Income TTM -217.5m / Revenue TTM 26.7m)
Gross Margin = 54.26% ((Revenue TTM 26.7m - Cost of Revenue TTM 12.2m) / Revenue TTM)
Gross Margin QoQ = 74.47% (prev 46.70%)
Tobins Q-Ratio = 2.17 (Enterprise Value 1.30b / Total Assets 601.6m)
Interest Expense / Debt = 0.87% (Interest Expense 501.0k / Debt 57.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -171.0m (EBIT -216.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.48 (Total Current Assets 577.5m / Total Current Liabilities 68.1m)
Debt / Equity = 0.18 (Debt 57.5m / totalStockholderEquity, last quarter 325.9m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -41.3m / EBITDA -215.0m)
Debt / FCF = 0.22 (negative FCF - burning cash) (Net Debt -41.3m / FCF TTM -190.2m)
Total Stockholder Equity = 395.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.08% (Net Income -217.5m / Total Assets 601.6m)
RoE = -54.99% (Net Income TTM -217.5m / Total Stockholder Equity 395.5m)
RoCE = -48.90% (EBIT -216.4m / Capital Employed (Equity 395.5m + L.T.Debt 47.1m))
RoIC = -40.25% (negative operating profit) (NOPAT -171.0m / Invested Capital 424.8m)
WACC = 10.30% (E(1.80b)/V(1.85b) * Re(10.61%) + D(57.5m)/V(1.85b) * Rd(0.87%) * (1-Tc(0.21)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.34%
Fair Price DCF = unknown (Cash Flow -190.2m)
EPS Correlation: 0.76 | EPS CAGR: 23.95% | SUE: 2.59 | # QB: 1
Revenue Correlation: 86.60 | Revenue CAGR: 119.9% | SUE: 2.88 | # QB: 7
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=+0.164 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.830 | Revisions Net=-1 | Growth EPS=+222.2% | Growth Revenue=+223.2%